NeoGenomics is trading 4.19% higher at $17.39 as investors position ahead of its October 28, 2026, third-quarter results.
- The company previously estimated Q3 revenue of approximately $209 million and NGS revenue growth of approximately 28%; these preliminary figures are not finalized results.
- Shares are also trading amid a broadly positive market, though company-specific earnings anticipation is the more direct explanation for the move.